Miyajima A, Ito K, Asano T, Seta K, Ueda A, Hayakawa M
Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan.
J Urol. 2001 Sep;166(3):1124-9.
We determined whether the cyclooxygenase-2 inhibitor etodolac affects renal tubular damage and interstitial fibrosis in unilateral ureteral obstruction.
Etodolac (10 mg./kg.) was administered to rats 1 day before unilateral ureteral obstruction and every day thereafter. Kidneys were harvested at day 14 after unilateral ureteral obstruction. Tissue transforming growth factor-beta and prostaglandin E2 were measured by bioassay using mink lung epithelial cells and enzyme linked immunosorbent-sandwich assay. Renal tubular proliferation and apoptosis were detected by immunostaining with proliferating cellular nuclear antigen and by terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate nick end labeling, respectively. Cyclooxygenase-2 expression was detected by immunohistochemistry. Fibrosis was assessed by measuring collagen deposition in trichrome stained slides.
Bioassay showed that in the control group obstructed kidneys contained significantly higher mean transforming growth factor-beta1 than unobstructed kidneys (79.1 +/- 8.3 versus 33.6 +/- 4.2 ng./gm. tissue) and etodolac significantly decrease the mean value in obstructed kidneys (46.2 +/- 10.0 ng./gm. tissue). Assay demonstrated that obstructed control kidneys had significantly more mean tubular apoptosis than their unobstructed counterparts (26.6 +/- 5.4 versus 2.2 +/- 1.4 nuclei per high power field) and etodolac significantly decreased mean renal tubular apoptosis in the obstructed kidneys (16.2 +/- 1.9 nuclei per high power field). In addition, immunostaining with proliferating cellular nuclear antigen showed that obstructed kidneys in the control group had significantly more mean renal tubular proliferation than unobstructed kidneys (9.8 +/- 3.4 versus 3.9 +/- 0.1 per high power field) and etodolac significantly increased mean proliferating renal tubule in the obstructed kidneys (24.9 +/- 4.3 per high power field). Control obstructed kidneys had significantly more fibrosis and prostaglandin E2 production, which were also significantly blunted by etodolac.
The cyclooxygenase-2 inhibitor etodolac significantly reduces tissue transforming growth factor-beta, resulting in decreased tubular damage and interstitial fibrosis. This finding suggests that etodolac is a promising agent for preventing renal tissue damage in unilateral ureteral obstruction.
我们确定环氧化酶-2抑制剂依托度酸是否会影响单侧输尿管梗阻时的肾小管损伤和间质纤维化。
在单侧输尿管梗阻前1天给大鼠施用依托度酸(10毫克/千克),此后每天给药。在单侧输尿管梗阻后第14天采集肾脏。使用貂肺上皮细胞通过生物测定法和酶联免疫吸附夹心测定法测量组织转化生长因子-β和前列腺素E2。分别通过用增殖细胞核抗原进行免疫染色和通过末端脱氧核苷酸转移酶介导的脱氧尿苷三磷酸缺口末端标记检测肾小管增殖和凋亡。通过免疫组织化学检测环氧化酶-2的表达。通过测量三色染色切片中的胶原沉积评估纤维化。
生物测定显示,在对照组中,梗阻肾脏中平均转化生长因子-β1含量明显高于未梗阻肾脏(79.1±8.3对33.6±4.2纳克/克组织),而依托度酸显著降低了梗阻肾脏中的平均值(46.2±10.0纳克/克组织)。测定表明,梗阻的对照肾脏的平均肾小管凋亡明显多于未梗阻的肾脏(每高倍视野26.6±5.4对2.2±1.4个细胞核),而依托度酸显著降低了梗阻肾脏中的平均肾小管凋亡(每高倍视野16.2±1.9个细胞核)。此外,用增殖细胞核抗原进行免疫染色显示,对照组中梗阻肾脏的平均肾小管增殖明显多于未梗阻肾脏(每高倍视野9.8±3.4对3.9±0.1),而依托度酸显著增加了梗阻肾脏中增殖肾小管的平均值(每高倍视野为24.9±出4.3)。对照梗阻肾脏的纤维化和前列腺素E2产生明显更多,依托度酸也使其显著减轻。
环氧化酶-2抑制剂依托度酸显著降低组织转化生长因子-β,从而减少肾小管损伤和间质纤维化。这一发现表明,依托度酸是预防单侧输尿管梗阻时肾组织损伤的一种有前景的药物。